Lenalidomide and dexamethasone (LEN plus DEX) treatment in relapsed/refractory multiple myeloma (RRMM) patients (pts) and risk of second primary malignancies (SPM): Analysis of MM-009/010.

8009 Background: MM is a chronic malignancy characterized by multiple relapses, and eventually, refractory disease. The phase III MM-009/010 trials demonstrated a significant survival benefit for L...